Personalized Medicine Market Size, Share & Trends Analysis Report By Product (Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness), By Region, And Segment- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The personalized medicine market size was estimated at USD 616.45 billion in 2022 and is expected to hit around USD 1,236.66 billion by 2032, poised to reach at a notable CAGR of 7.21% during the forecast period 2023 to 2032.

Personalized Medicine Market Size, 2023 to 2032 (USD Billion )

Key Takeaways:

  • North America accounted for the largest market share of 48.24% in 2022
  • Asia Pacific is projected to grow at the fastest CAGR of 8.52% over the forecast period
  • Personalized nutrition & wellness recorded a dominant market share of 57.92% in 2022.
  • The personalized medicine therapeutics segment is projected to record the fastest CAGR of 10.72% over the forecast period.
  • The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe

Personalized Medicine Market Report Scope

Report Attribute Details
Market Size in 2023 USD 660.9 Billion
Market Size by 2032 USD 1,236.66 Billion
Growth Rate From 2023 to 2032 CAGR of 7.21%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled GE Healthcare; Illumina, Inc.; ASURAGEN, INC.; Abbott; Dako A/S; Exact Sciences Corporation; Danaher Corporation (Cepheid, Inc.); Decode Genetics, Inc.; QIAGEN; Exagen Inc.; Precision Biologics; Celera Diagnostics LLC; Biogen; Genelex; IBM; Genentech, Inc.; 23andMe, Inc.

 

The increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual’s genome, diet, microbiota, and associative environmental factors.

Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.

The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.

Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.

Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.

The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.

Product Insights

Personalized nutrition & wellness recorded a dominant market share of 57.92% in 2022. The growth of the segment is due to extensive consumption rate and market penetration. Further, the high rate of over the counter (OTC) sales of nutrition products boost the demand due to lowered regulatory implications. For instance, in March 2022, the American Heart Association features that the nutrition scientists are working towards precision nutrition to combat cardiovascular diseases based on the unique responses for specific foods and nutrients.

The personalized medicine therapeutics segment is projected to record the fastest CAGR of 10.72% over the forecast period. The rise in demand for genomics based therapeutics and the biopharmaceuticals based on specifically sequenced data is primarily attributed to the growth of the segment. Moreover, the emergence of high-end sequencing to effectively reduce the cost of genome sequencing, nurtures the growth of the market.

Regional Insights

North America accounted for the largest market share of 48.24% in 2022. This is attributive to the support by research institutes and the pharmaceutical giants. Personalized medicine is now preferred for all kinds of diseases and therefore is part of research on any given disease and drug discovery. There are emerging advancements in personalized medicine for diagnostics in the region. For instance, in January 2021, Illumina, Inc. develops the TruSight Oncology 500 (TSO 500) assay that uses nucleic acids from tumor region and capably identifies as many as 523 cancer biomarkers.

Asia Pacific is projected to grow at the fastest CAGR of 8.52% over the forecast period due to increased demand for personalized medicine in diagnostics and the growing demand for novel therapeutic drugs to fight increased incidence of diseases in the region.

Recent Development

  • In July 2023, 23andMe released a new Simvastatin Medication Insight report, part of a suite of 23andMe reports that look into how genetics can impact the response to certain medications for people, as well as their chance of possible side effects. The Simvastatin Medication Insight report looks at individual responses to simvastatin, a statin drug for lowering blood cholesterol, which is also known by brand names like Zocor and Flolipid
  • In June 2023, Qiagen announced that the ‘QCI Interpret’ software had been selected by the Danish National Genome Center for providing sequencing-based solutions for cancer patients. The variant interpretation and reporting software had been chosen for interpreting oncology results extracted from whole-genome sequencing data. This development is part of Denmark’s personalized medicine strategy for offering WGS as the standard-of-care for relevant patient groups
  • In June 2023, GE Healthcare showcased its latest solutions in the areas of precision care and personalized medicine at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting. In the personalized medicine area, the company launched the SIGNA PET/MR system, which has been designed to aid clinicians in seeing the smallest lesions, research new tracers, and plan more accurate treatment paths for each patient
  • In June 2023, Illumina launched its new PrimateAI-3D AI algorithm, which predicts disease-causing genetic mutations in patients with a high accuracy. The algorithm uses deep neural network architectures and is trained on genome sequences. PrimateAI-3D aims to address the challenges facing the successful implementation of personalized genomic medicine through offering accurate predictions regarding disease-causing variants
  • In April 2023, Precision Biologics announced the publication of its first in-human Phase I clinical trial with its novel monoclonal antibody, NEO-201. The trial was conducted in patients with refractory solid tumors. The NEO-201 was able to reduce immune suppressive cells that can be responsible in reducing the cancer-killing activity for checkpoint inhibitors such as Keytruda
  • In November 2022, Danaher Corporation entered into a strategic partnership with Duke University for its first Danaher Beacon for Gene Therapy Innovation. The Danaher Beacons initiative has been designed to leverage breakthrough science for developing applications and technologies that improve human health, with major focus areas being genomic medicines, precision diagnostics, next-gen biomanufacturing, and data sciences
  • In August 2022, Exagen launched the ‘TiGER’ study for validating a novel and minimally invasive genomic diagnostic test for rheumatoid arthritis, using the AVISE RADR platform. The study will aid in identifying biomarkers in the synovial tissue for drug response in rheumatoid arthritis, helping in the development of personalized medicine for treating the disorder and establishing it as the primary form of care

Some of the prominent players in the Personalized Medicine Market include:

  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation (Cepheid, Inc.)
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC.
  • Biogen
  • Genelex
  • International Business Machines Corporation (IBM)
  • Genentech, Inc.
  • 23andMe, Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Personalized Medicine market.

By Product 

  • Personalized Medicine Diagnostics
    • Genetic Testing
    • Direct-To-Consumer (DTC) Diagnostics
    • Esoteric Lab Services
    • Esoteric Lab Tests
  • Personalized Medicine Therapeutics
    • Pharmaceutical
    • Genomic Medicine
    • Medical Devices
  • Personalized Medical Care
    • Telemedicine
    • Health Information Technology
  • Personalized Nutrition & Wellness
    • Retail Nutrition
    • Complementary & Alternative Medicine

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The personalized medicine market size was estimated at USD 616.45 billion in 2022 and is expected to hit around USD 1,236.66 billion by 2032

The global personalized medicine market is expected to grow at a compound annual growth rate of 7.21% from 2023 to 2032

Some key players operating in the personalized medicine market include GE Healthcare, Illumina, Inc., ASURAGEN, INC., Abbott, Dako A/S, Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), Decode Genetics, Inc., QIAGEN, Exagen Inc., Precision Biologics, Celera Diagnostics LLC, Biogen, Genelex, IBM, Genentech, Inc., 23andMe, Inc.

Key factors that are driving the personalized medicine market growth include the advancement of next-generation sequencing, a growing number of companion/associated diagnostics, an increasing number of retail clinics across the developed regions of North America and Europe, an increasing prevalence of cancer, and increasing usage of biomarkers for PM cancer therapy.

Chapter 1. Methodology and Scope
                    1.1. Information Procurement
                    1.2. Information Or Data Analysis
                    1.3. Market Scope & Segment Definition
                    1.4. Market Model
                         1.4.1. Market Study, By Company Market Share
                         1.4.2. Regional Analysis
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                         3.1.1. Parent Market Outlook
                         3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Dynamics
                         3.2.1. Market Driver Analysis
                              3.2.1.1. Utility Of Human Genome Data For Clinical Research
                                   3.2.1.1.1. Targeted And Personalized Healthcare
                              3.2.1.2. Technological Advancements To Facilitate R&D For Personalized Medicine
                                   3.2.1.2.1. Emergence Of Advanced Genome Editing Techniques
                                   3.2.1.2.2. Utility Of Novel Databases For Research
                         3.2.2. Market Restraint Analysis
                              3.2.2.1. Ethical Issues And Protection Of Individual’s Genomic Data
                              3.2.2.2. Limited Access To Human Genome Data And Databases
                         3.2.3. Market Opportunity Analysis
                    3.3. Industry Analysis Tools
                         3.3.1. Porter’s Five Forces Analysis
                         3.3.2. PESTEL Analysis
                         3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
                    4.1. Personalized Medicine Market: Product Movement Analysis
                    4.2. Personalized Medicine Diagnostics
                         4.2.1. Personalized Medicine Diagnostics Market, 2020 - 2032
                         4.2.2. Genetic Testing
                              4.2.2.1. Genetic Testing Market, 2020 - 2032
                         4.2.3. Direct-To-Consumer (DTC) Diagnostics
                              4.2.3.1. Direct-To-Consumer (DTC) Diagnostics Market, 2020 - 2032
                         4.2.4. Esoteric Lab Services
                              4.2.4.1. Esoteric Lab Services Market, 2020 - 2032
                         4.2.5. Esoteric Lab Tests
                              4.2.5.1. Esoteric Lab Tests Market, 2020 - 2032
                    4.3. Personalized Medicine Therapeutics
                         4.3.1. Personalized Medicine Therapeutics Market, 2020 - 2032
                         4.3.2. Pharmaceutical
                              4.3.2.1. Pharamceutical Market, 2020 - 2032
                         4.3.3. Genomic Medicine
                              4.3.3.1. Genomic Medicine Market, 2020 - 2032
                         4.3.4. Medical Devices
                              4.3.4.1. Medical Devices Market, 2020 - 2032
                    4.4. Personalized Medical Care
                         4.4.1. Personlaized Medical Care Market, 2020 - 2032
                         4.4.2. Telemedicine
                              4.4.2.1. Telemedicine Market, 2020 - 2032
                         4.4.3. Health Information Technology
                              4.4.3.1. Health Inforamtion Technology Market, 2020 - 2032
                    4.5. Personalized Nutrition & Wellness
                         4.5.1. Personalzied Nutrtion & Wellness Market, 2020 - 2032
                         4.5.2. Retail Nutrition
                              4.5.2.1. Retail Nutrition Market, 2020 - 2032
                         4.5.3. Complementary & Alternative Medicine
                              4.5.3.1. Complementary & Alternative Medicine Market, 2020 - 2032
Chapter 5. Regional Business Analysis
                    5.1. Personalized Medicine Market Share By Region, 2022 & 2030
                    5.2. North America
                         5.2.1. SWOT Analysis
                         5.2.2. North America Personalized Medicine Market, 2020 - 2032
                         5.2.3. U.S.
                              5.2.3.1. Key Country Dynamics
                              5.2.3.2. Target Disease Prevalence
                              5.2.3.3. Competitive Scenario
                              5.2.3.4. Regulatory Framework
                              5.2.3.5. Reimbursement Scenario
                              5.2.3.6. U.S. Personalized Medicine Market, 2020 - 2032
                         5.2.4. Canada
                              5.2.4.1. Key Country Dynamics
                              5.2.4.2. Target Disease Prevalence
                              5.2.4.3. Competitive Scenario
                              5.2.4.4. Regulatory Framework
                              5.2.4.5. Reimbursement Scenario
                              5.2.4.6. Canada Personalized Medicine Market, 2020 - 2032
                    5.3. Europe
                         5.3.1. SWOT Analysis
                         5.3.2. Europe Personalized Medicine Market, 2020 - 2032
                         5.3.3. UK
                              5.3.3.1. Key Country Dynamics
                              5.3.3.2. Target Disease Prevalence
                              5.3.3.3. Competitive Scenario
                              5.3.3.4. Regulatory Framework
                              5.3.3.5. Reimbursement Scenario
                              5.3.3.6. UK Personalized Medicine Market, 2020 - 2032
                         5.3.4. Germany
                              5.3.4.1. Key Country Dynamics
                              5.3.4.2. Target Disease Prevalence
                              5.3.4.3. Competitive Scenario
                              5.3.4.4. Regulatory Framework
                              5.3.4.5. Reimbursement Scenario
                              5.3.4.6. Germany Personalized Medicine Market, 2020 - 2032
                         5.3.5. France
                              5.3.5.1. Key Country Dynamics
                              5.3.5.2. Target Disease Prevalence
                              5.3.5.3. Competitive Scenario
                              5.3.5.4. Regulatory Framework
                              5.3.5.5. Reimbursement Scenario
                              5.3.5.6. France Personalized Medicine Market, 2020 - 2032
                         5.3.6. Italy
                              5.3.6.1. Key Country Dynamics
                              5.3.6.2. Target Disease Prevalence
                              5.3.6.3. Competitive Scenario
                              5.3.6.4. Regulatory Framework
                              5.3.6.5. Reimbursement Scenario
                              5.3.6.6. Italy Personalized Medicine Market, 2020 - 2032
                         5.3.7. Spain
                              5.3.7.1. Key Country Dynamics
                              5.3.7.2. Target Disease Prevalence
                              5.3.7.3. Competitive Scenario
                              5.3.7.4. Regulatory Framework
                              5.3.7.5. Reimbursement Scenario
                              5.3.7.6. Spain Personalized Medicine Market, 2020 - 2032
                         5.3.8. Denmark
                              5.3.8.1. Key Country Dynamics
                              5.3.8.2. Target Disease Prevalence
                              5.3.8.3. Competitive Scenario
                              5.3.8.4. Regulatory Framework
                              5.3.8.5. Reimbursement Scenario
                              5.3.8.6. Denmark Personalized Medicine Market, 2020 - 2032
                         5.3.9. Sweden
                              5.3.9.1. Key Country Dynamics
                              5.3.9.2. Target Disease Prevalence
                              5.3.9.3. Competitive Scenario
                              5.3.9.4. Regulatory Framework
                              5.3.9.5. Reimbursement Scenario
                              5.3.9.6. Sweden Personalized Medicine Market, 2020 - 2032
                         5.3.10. Norway
                              5.3.10.1. Key Country Dynamics
                              5.3.10.2. Target Disease Prevalence
                              5.3.10.3. Competitive Scenario
                              5.3.10.4. Regulatory Framework
                              5.3.10.5. Reimbursement Scenario
                              5.3.10.6. Norway Personalized Medicine Market, 2020 - 2032
                    5.4. Asia Pacific
                         5.4.1. SWOT Analysis
                         5.4.2. Asia Pacific Personalized Medicine Market, 2020 - 2032
                         5.4.3. Japan
                              5.4.3.1. Key Country Dynamics
                              5.4.3.2. Target Disease Prevalence
                              5.4.3.3. Competitive Scenario
                              5.4.3.4. Regulatory Framework
                              5.4.3.5. Reimbursement Scenario
                              5.4.3.6. Japan Personalized Medicine Market, 2020 - 2032
                         5.4.4. China
                              5.4.4.1. Key Country Dynamics
                              5.4.4.2. Target Disease Prevalence
                              5.4.4.3. Competitive Scenario
                              5.4.4.4. Regulatory Framework
                              5.4.4.5. Reimbursement Scenario
                              5.4.4.6. China Personalized Medicine Market, 2020 - 2032
                         5.4.5. India
                              5.4.5.1. Key Country Dynamics
                              5.4.5.2. Target Disease Prevalence
                              5.4.5.3. Competitive Scenario
                              5.4.5.4. Regulatory Framework
                              5.4.5.5. Reimbursement Scenario
                              5.4.5.6. India Personalized Medicine Market, 2020 - 2032
                         5.4.6. Australia
                              5.4.6.1. Key Country Dynamics
                              5.4.6.2. Target Disease Prevalence
                              5.4.6.3. Competitive Scenario
                              5.4.6.4. Regulatory Framework
                              5.4.6.5. Reimbursement Scenario
                              5.4.6.6. Australia Personalized Medicine Market, 2020 - 2032
                         5.4.7. Thailand
                              5.4.7.1. Key Country Dynamics
                              5.4.7.2. Target Disease Prevalence
                              5.4.7.3. Competitive Scenario
                              5.4.7.4. Regulatory Framework
                              5.4.7.5. Reimbursement Scenario
                              5.4.7.6. Thailand Personalized Medicine Market, 2020 - 2032
                         5.4.8. South Korea
                              5.4.8.1. Key Country Dynamics
                              5.4.8.2. Target Disease Prevalence
                              5.4.8.3. Competitive Scenario
                              5.4.8.4. Regulatory Framework
                              5.4.8.5. Reimbursement Scenario
                              5.4.8.6. South Korea Personalized Medicine Market, 2020 - 2032
                    5.5. Latin America
                         5.5.1. SWOT Analysis
                         5.5.2. Latin America Personalized Medicine Market, 2020 - 2032
                         5.5.3. Brazil
                              5.5.3.1. Key Country Dynamics
                              5.5.3.2. Target Disease Prevalence
                              5.5.3.3. Competitive Scenario
                              5.5.3.4. Regulatory Framework
                              5.5.3.5. Reimbursement Scenario
                              5.5.3.6. Brazil Personalized Medicine Market, 2020 - 2032
                         5.5.4. Mexico
                              5.5.4.1. Key Country Dynamics
                              5.5.4.2. Target Disease Prevalence
                              5.5.4.3. Competitive Scenario
                              5.5.4.4. Regulatory Framework
                              5.5.4.5. Reimbursement Scenario
                              5.5.4.6. Mexico Personalized Medicine Market, 2020 - 2032
                         5.5.5. Argentina
                              5.5.5.1. Key Country Dynamics
                              5.5.5.2. Target Disease Prevalence
                              5.5.5.3. Competitive Scenario
                              5.5.5.4. Regulatory Framework
                              5.5.5.5. Reimbursement Scenario
                              5.5.5.6. Argentina Personalized Medicine Market, 2020 - 2032
                    5.6. MEA
                         5.6.1. SWOT Analysis
                         5.6.2. MEA Personalized Medicine Market, 2020 - 2032
                         5.6.3. South Africa
                              5.6.3.1. Key Country Dynamics
                              5.6.3.2. Target Disease Prevalence
                              5.6.3.3. Competitive Scenario
                              5.6.3.4. Regulatory Framework
                              5.6.3.5. Reimbursement Scenario
                              5.6.3.6. South Africa Personalized Medicine Market, 2020 - 2032
                         5.6.4. Saudi Arabia
                              5.6.4.1. Key Country Dynamics
                              5.6.4.2. Target Disease Prevalence
                              5.6.4.3. Competitive Scenario
                              5.6.4.4. Regulatory Framework
                              5.6.4.5. Reimbursement Scenario
                              5.6.4.6. Saudi Arabia Personalized Medicine Market, 2020 - 2032
                         5.6.5. UAE
                              5.6.5.1. Key Country Dynamics
                              5.6.5.2. Target Disease Prevalence
                              5.6.5.3. Competitive Scenario
                              5.6.5.4. Regulatory Framework
                              5.6.5.5. Reimbursement Scenario
                              5.6.5.6. UAE Personalized Medicine Market, 2020 - 2032
                         5.6.6. Kuwait
                              5.6.6.1. Key Country Dynamics
                              5.6.6.2. Target Disease Prevalence
                              5.6.6.3. Competitive Scenario
                              5.6.6.4. Regulatory Framework
                              5.6.6.5. Reimbursement Scenario
                              5.6.6.6. Kuwait Personalized Medicine Market, 2020 - 2032
Chapter 6. Competitive Landscape
                    6.1. Company Categorization
                    6.2. Strategy Mapping
                    6.3. Company Market Share Analysis, 2022
                    6.4. Company Profiles/Listing
                         6.4.1. GE Healthcare
                              6.4.1.1. Overview
                              6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.1.3. Product Benchmarking
                              6.4.1.4. Strategic Initiatives
                         6.4.2. Illumina, Inc.
                              6.4.2.1. Overview
                              6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.2.3. Product Benchmarking
                              6.4.2.4. Strategic Initiatives
                         6.4.3. ASURAGEN, INC.
                              6.4.3.1. Overview
                              6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.3.3. Product Benchmarking
                              6.4.3.4. Strategic Initiatives
                         6.4.4. Abbott
                              6.4.4.1. Overview
                              6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.4.3. Product Benchmarking
                              6.4.4.4. Strategic Initiatives
                         6.4.5. Dako A/S
                              6.4.5.1. Overview
                              6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.5.3. Product Benchmarking
                              6.4.5.4. Strategic Initiatives
                         6.4.6. Exact Sciences Corporation
                              6.4.6.1. Overview
                              6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.6.3. Product Benchmarking
                              6.4.6.4. Strategic Initiatives
                         6.4.7. Danaher Corporation (Cepheid, Inc.)
                              6.4.7.1. Overview
                              6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.7.3. Product Benchmarking
                              6.4.7.4. Strategic Initiatives
                         6.4.8. Decode Genetics, Inc.
                              6.4.8.1. Overview
                              6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.8.3. Product Benchmarking
                              6.4.8.4. Strategic Initiatives
                         6.4.9. QIAGEN
                              6.4.9.1. Overview
                              6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.9.3. Product Benchmarking
                              6.4.9.4. Strategic Initiatives
                         6.4.10. Exagen Inc.
                              6.4.10.1. Overview
                              6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.10.3. Product Benchmarking
                              6.4.10.4. Strategic Initiatives
                         6.4.11. Precision Biologics
                              6.4.11.1. Overview
                              6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.11.3. Product Benchmarking
                              6.4.11.4. Strategic Initiatives
                         6.4.12. Celera Diagnostics LLC
                              6.4.12.1. Overview
                              6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.12.3. Product Benchmarking
                              6.4.12.4. Strategic Initiatives
                         6.4.13. Biogen
                              6.4.13.1. Overview
                              6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.13.3. Product Benchmarking
                              6.4.13.4. Strategic Initiatives
                         6.4.14. Genelex
                              6.4.14.1. Overview
                              6.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.14.3. Product Benchmarking
                              6.4.14.4. Strategic Initiatives
                         6.4.15. IBM
                              6.4.15.1. Overview
                              6.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.15.3. Product Benchmarking
                              6.4.15.4. Strategic Initiatives
                         6.4.16. Genentech, Inc.
                              6.4.16.1. Overview
                              6.4.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.16.3. Product Benchmarking
                              6.4.16.4. Strategic Initiatives
                         6.4.17. 23andMe, Inc.
                              6.4.17.1. Overview
                              6.4.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                              6.4.17.3. Product Benchmarking
                              6.4.17.4. Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert